Krishanu Saha

List of Publications by Year
in descending order

73 papers	7,297 citations	147801 31 h-index	95266 68 g-index
82 all docs	82 docs citations	82 times ranked	10587 citing authors

#	Article	IF	Citations
1	Controlling CRISPR with small molecule regulation for somatic cell genome editing. Molecular Therapy, 2022, 30, 17-31.	8.2	8
2	Label-Free Imaging to Track Reprogramming of Human Somatic Cells. , 2022, 1, 176-191.		1
3	In situ autofluorescence lifetime assay of a photoreceptor stimulus response in mouse retina and human retinal organoids. Biomedical Optics Express, 2022, 13, 3476.	2.9	5
4	Classification of T-cell activation via autofluorescence lifetime imaging. Nature Biomedical Engineering, 2021, 5, 77-88.	22.5	92
5	The NIH Somatic Cell Genome Editing program. Nature, 2021, 592, 195-204.	27.8	84
6	Integrating Biomaterials and Genome Editing Approaches to Advance Biomedical Science. Annual Review of Biomedical Engineering, 2021, 23, 493-516.	12.3	4
7	Single-cell technologies to dissect heterogenous immune cell therapy products. Current Opinion in Biomedical Engineering, 2021, 20, 100343.	3.4	1
8	Machine learning approach to measurement of criticism: The core dimension of expressed emotion.. Journal of Family Psychology, 2021, 35, 1007-1015.	1.3	2
9	Psychobiology of Stress and Adolescent Depression (PSY SAD) Study: Protocol overview for an fMRI-based multi-method investigation. Brain, Behavior, & Immunity - Health, 2021, 17, 100334.	2.5	2
10	Carbomer-based adjuvant elicits CD8 T-cell immunity by inducing a distinct metabolic state in cross-presenting dendritic cells. PLoS Pathogens, 2021, 17, e1009168.	4.7	19
11	Tracking and Predicting Human Somatic Cell Reprogramming Using Nuclear Characteristics. Biophysical Journal, 2020, 118, 2086-2102.	0.5	6
12	Human iPSC Modeling Reveals Mutation-Specific Responses to Gene Therapy in a Genotypically Diverse Dominant Maculopathy. American Journal of Human Genetics, 2020, 107, 278-292.	6.2	35
13	Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases. Nature Communications, 2020, 11, 6277.	12.8	7
14	Constitutionalism at the Nexus of Life and Law. Science Technology and Human Values, 2020, 45, 979-1000.	3.1	17
15	A pH-responsive silicaâ€“metalâ€“organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries. Journal of Controlled Release, 2020, 324, 194-203.	9.9	55
16	Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies. Stem Cell Research and Therapy, 2020, 11, 234.	5.5	55
17	Democratic Governance of Human Germline Genome Editing. CRISPR Journal, 2019, 2, 266-271.	2.9	27
18	Data-driven phenotype discovery of <i>FMR1</i> premutation carriers in a population-based sample. Science Advances, 2019, 5, eaaw7195.	10.3	33

#	Article	IF	Citations
19	A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Nature Nanotechnology, 2019, 14, 974-980.	31.5	252
20	Multi-cellular engineered living systems: building a community around responsible research on emergence. Biofabrication, 2019, 11, 043001.	7.1	13
21	CRISPR/Cas9 editing of APP C-terminus attenuates Î²-cleavage and promotes Î±-cleavage. Nature Communications, 2019, 10, 53.	12.8	81
22	Scarless Genome Editing of Human Pluripotent Stem Cells via Transient Puromycin Selection. Stem Cell Reports, 2018, 10, 642-654.	4.8	58
23	Fairness in Manufacturing Cellular Therapies. American Journal of Bioethics, 2018, 18, 68-70.	0.9	2
24	Developing precision medicine using scarless genome editing of human pluripotent stem cells. Drug Discovery Today: Technologies, 2018, 28, 3-12.	4.0	7
25	Bioengineering Solutions for Manufacturing Challenges in CAR T Cells. Biotechnology Journal, 2018, 13, 1700095.	3.5	56
26	The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1573-1584.	2.0	16
27	Response to Beriain. Trends in Biotechnology, 2018, 36, 1206-1207.	9.3	0
28	Versatile Redox-Responsive Polyplexes for the Delivery of Plasmid DNA, Messenger RNA, and CRISPR-Cas9 Genome-Editing Machinery. ACS Applied Materials & Interfaces, 2018, 10, 31915-31927.	8.0	49
29	Increasing the precision of gene editing inÂvitro, exÂvivo, and inÂvivo. Current Opinion in Biomedical Engineering, 2018, 7, 83-90.	3.4	8
30	Building Capacity for a Global Genome Editing Observatory: Conceptual Challenges. Trends in Biotechnology, 2018, 36, 639-641.	9.3	28
31	Building Capacity for a Global Genome Editing Observatory: Institutional Design. Trends in Biotechnology, 2018, 36, 741-743.	9.3	23
32	Genome Editing in Human Pluripotent Stem Cells. Methods in Molecular Biology, 2017, 1590, 165-174.	0.9	4
33	The inconvenience of data of convenience: computational research beyond post-mortem analyses. Nature Methods, 2017, 14, 937-938.	19.0	9
34	Automated screening for Fragile X premutation carriers based on linguistic and cognitive computational phenotypes. Scientific Reports, 2017, 7, 2674.	3.3	11
35	Assembly of CRISPR ribonucleoproteins with biotinylated oligonucleotides via an RNA aptamer for precise gene editing. Nature Communications, 2017, 8, 1711.	12.8	121
36	Manufacturing Cell Therapies Using Engineered Biomaterials. Trends in Biotechnology, 2017, 35, 971-982.	9.3	35

#	Article	IF	Citations
37	Establishment of Reporter Lines for Detecting Fragile X Mental Retardation (<i>FMR1</i>) Gene Reactivation in Human Neural Cells. Stem Cells, 2017, 35, 158-169.	3.2	44
38	Manufacturing Cell Therapies: The Paradigm Shift in Health Care of This Century. NAM Perspectives, 2017, 7, .	2.9	23
39	575. High Content Analysis of CRISPR-Cas9 Gene-Edited Human Embryonic Stem Cells. Molecular Therapy, 2016, 24, S229-S230.	8.2	0
40	335. High Content Analysis Platform for Optimization of Lipid Mediated CRISPR-Cas9 Delivery Strategies in Human Cells. Molecular Therapy, 2016, 24, S133.	8.2	0
41	High-Content Analysis of CRISPR-Cas9 Gene-Edited Human Embryonic Stem Cells. Stem Cell Reports, 2016, 6, 109-120.	4.8	23
42	High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells. Acta Biomaterialia, 2016, 34, 143-158.	8.3	25
43	Highâ€content imaging with micropatterned multiwell plates reveals influence of cell geometry and cytoskeleton on chromatin dynamics. Biotechnology Journal, 2015, 10, 1555-1567.	3.5	24
44	Î±-5 Laminin Synthesized by Human Pluripotent Stem Cells Promotes Self-Renewal. Stem Cell Reports, 2015, 5, 195-206.	4.8	59
45	Strategies from UW-Madison for rescuing biomedical research in the US. ELife, 2015, 4, e09305.	6.0	30
46	Drug-loaded nanoparticles induce gene expression in human pluripotent stem cell derivatives. Nanoscale, 2014, 6, 521-531.	5.6	26
47	Nanofibrous Electrospun Polymers for Reprogramming Human Cells. Cellular and Molecular Bioengineering, 2014, 7, 379-393.	2.1	18
48	Allying with Donors to Link Health and Medical Information with Stem Cell Lines Can Advance Disease Modeling while Enhancing Data Access. Cell Stem Cell, 2014, 14, 559-560.	11.1	6
49	A stochastic model dissects cell states in biological transition processes. Scientific Reports, 2014, 4, 3692.	3.3	24
50	Effect of thickness and Ti interlayers on stresses and texture transformations in thin Ag films during thermal cycling. Applied Physics Letters, 2013, 103, 191905.	3.3	5
51	Access to Stem Cells and Data: Persons, Property Rights, and Scientific Progress. Science, 2011, 331, 725-727.	12.6	28
52	Surface-engineered substrates for improved human pluripotent stem cell culture under fully defined conditions. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18714-18719.	7.1	137
53	Treat donors as partners in biobank research. Nature, 2011, 478, 312-313.	27.8	37
54	Disease modeling using pluripotent stem cells: making sense of disease from bench to bedside. Swiss Medical Weekly, 2011, 141, w13144.	1.6	10

#	Article	IF	Citations
55	Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. Nature Materials, 2010, 9, 768-778.	27.5	504
56	Surface Creasing Instability of Soft Polyacrylamide Cell Culture Substrates. Biophysical Journal, 2010, 99, L94-L96.	0.5	72
57	Pluripotency and Cellular Reprogramming: Facts, Hypotheses, Unresolved Issues. Cell, 2010, 143, 508-525.	28.9	635
58	Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9222-9227.	7.1	755
59	Direct cell reprogramming is a stochastic process amenable to acceleration. Nature, 2009, 462, 595-601.	27.8	936
60	Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease. Cell Stem Cell, 2009, 5, 584-595.	11.1	379
61	Reprogramming of murine and human somatic cells using a single polycistronic vector. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 157-162.	7.1	453
62	Opening stem cell research and development: a policy proposal for the management of data, intellectual property, and ethics. Yale Journal of Health Policy, Law, and Ethics, 2009, 9, 52-127.	1.5	14
63	Substrate Modulus Directs Neural Stem Cell Behavior. Biophysical Journal, 2008, 95, 4426-4438.	0.5	947
64	Multivalency of Sonic Hedgehog Conjugated to Linear Polymer Chains Modulates Protein Potency. Bioconjugate Chemistry, 2008, 19, 806-812.	3.6	50
65	Modulus-dependent macrophage adhesion and behavior. Journal of Biomaterials Science, Polymer Edition, 2008, 19, 1363-1382.	3.5	87
66	Biomimetic interfacial interpenetrating polymer networks control neural stem cell behavior. Journal of Biomedical Materials Research - Part A, 2007, 81A, 240-249.	4.0	97
67	Designing synthetic materials to control stem cell phenotype. Current Opinion in Chemical Biology, 2007, 11, 381-387.	6.1	208
68	Signal dynamics in Sonic hedgehog tissue patterning. Development (Cambridge), 2006, 133, 1411-1411.	2.5	5
69	Signal dynamics in Sonic hedgehog tissue patterning. Development (Cambridge), 2006, 133, 889-900.	2.5	107
70	Sensitivity of the acoustic waveguide biosensor to protein binding as a function of the waveguide properties. Biosensors and Bioelectronics, 2003, 18, 1399-1406.	10.1	97
71	Comparative Study of IgG Binding to Proteins G and A:Â Nonequilibrium Kinetic and Binding Constant Determination with the Acoustic Waveguide Device. Analytical Chemistry, 2003, 75, 835-842.	6.5	161
72	Probing the Viscoelasticity and Mass of a Surface-Bound Protein Layer with an Acoustic Waveguide Device. Langmuir, 2003, 19, 1304-1311.	3.5	35

#	Article	IF	Citations
73	A CRISPR/Cas9 Based Strategy to Manipulate the Alzheimerrs Amyloid Pathway. SSRN Electronic Journal, 0, , .	0.4	1